SELECT MEDICAL HOLDINGS CORP 8-K

What Happened
Select Medical Holdings Corporation (SEM) announced on March 2, 2026 (filed 8-K March 3, 2026) that it entered into an Agreement and Plan of Merger with Stallion Intermediate Corporation (Parent) and its wholly owned Merger Sub. Under the Merger Agreement, Merger Sub will merge into Select Medical and each outstanding common share (except certain rollover, treasury or appraisal shares) will be converted into the right to receive $16.50 per share in cash. A Special Committee of disinterested directors unanimously recommended the transaction and the Board has approved it and will submit it to stockholders for a vote.

Key Details

• Agreement date: March 2, 2026; filing date: March 3, 2026.
• Merger consideration: $16.50 cash per outstanding share (no interest).
• Closing conditions include stockholder approval, regulatory and healthcare approvals (including HSR clearance), and absence of legal restraints; closing will result in NYSE delisting and deregistration under the Exchange Act.
• Financing: committed equity from WCAS XIV, L.P. (Equity Investor) and debt commitments from lenders; the Equity Investor provided a Limited Guaranty covering certain Parent obligations. The Merger Agreement itself contains no financing condition.
• Termination / fees: Outside Date of Dec 1, 2026 (auto-extendable to Mar 1, 2027 in certain cases). Company may pay Parent a $66,504,813 termination fee in specified sale/solicit circumstances; Parent may owe the Company $133,009,627 if Parent fails to close after conditions are met and the Company is ready to close.

Why It Matters
For shareholders, this is a cash buyout at $16.50 per share that, if approved and closed, would take Select Medical private, remove its NYSE listing, and end public trading and public reporting obligations. The special committee and Board support the deal; closing depends on a shareholder vote and regulatory approvals (including antitrust and healthcare clearances). Financing commitments and a guaranty were disclosed, and sizable termination fees are in place, which indicate deal protections and potential costs if the transaction is broken. Investors should watch for the Company’s proxy filing for full transaction details, the timing of the shareholder vote, and any regulatory developments.